ULTRAGENYX PHARMACEUTICAL IN Business Summary

Ultragenyx Pharmaceutical Inc. (RARE) is a commercial-stage biopharmaceutical company that generates revenue primarily through the global sale of its approved therapies for rare and ultra-rare genetic diseases, including Crysvita (for X-linked hypophosphatemia), Dojolvi (for molecularly confirmed long-chain fatty acid oxidation disorders), and Evkeeza (for homozygous familial hypercholesterolemia). The company’s business model is built on a vertically integrated approach, spanning early-stage research to commercial distribution, with primary segments focused on metabolic, bone, and neuromuscular diseases. As of early 2026, Ultragenyx is transitioning toward a path of profitability by 2027, supported by a strategic restructuring and a robust pipeline of gene therapies and enzyme replacements. It competes directly with specialized rare disease players such as BioMarin Pharmaceutical, Sarepta Therapeutics, Alnylam Pharmaceuticals, and BridgeBio Pharma, maintaining a competitive edge through its focus on ultra-rare indications with high unmet medical needs and clear biological targets. The company was founded in 2010 by Dr. Emil D. Kakkis, a pioneer in the rare disease space who previously served as Chief Medical Officer at BioMarin and founded the EveryLife Foundation for Rare Diseases. The current leadership team is led by Dr. Kakkis as President and CEO, supported by Howard Horn as Chief Financial Officer and EVP of Corporate Strategy, Dr. Eric Crombez as Chief Medical Officer, and Dennis Huang as Chief Technical Operations Officer and EVP of Gene Therapy R&D. Recent key appointments include Eric Olson as Chief Business Officer, who joined in late 2025 to oversee corporate development. The company’s board is chaired by Daniel G. Welch and includes notable industry veterans such as Dr. Deborah Dunsire and Michael Narachi. Ultragenyx maintains a high level of institutional backing, with over 97% of shares held by major investment firms, and has historically secured strategic funding and royalty deals from entities like TPG and Royalty Pharma.